Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl

12/03/2021 | 07:31am EST

By Chris Wack

Bristol Myers Squibb said the U.S. Food and Drug Administration has accepted for priority review its supplemental Biologics License Application for Reblozyl luspatercept-aamt for the treatment of anemia in adults with non-transfusion dependent beta thalassemia.

The company said the FDA has set a Prescription Drug User Fee Act goal date of March 27, 2022.

Bristol Myers also said the European Medicines Agency has validated the Type II variation for Reblozyl in NTD beta thalassemia. Reblozyl is being co-developed and co-commercialized with Merck & Co. Inc. following Merck's recent acquisition of Acceleron Pharma Inc.

These applications were based on safety and efficacy results from a Phase 2 study evaluating Reblozyl plus best supportive care in patients with NTD beta thalassemia.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

12-03-21 0731ET

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY -1.61% 63.54 Delayed Quote.3.58%
CORN FUTURES (C) - CBR (FLOOR)/C1 0.86% 616.25 End-of-day quote.2.99%
MERCK & CO., INC. -0.95% 79.98 Delayed Quote.4.36%
All news about BRISTOL-MYERS SQUIBB COMPANY
01/20BRISTOL MYERS SQUIBB : Receives Approval for Abecma (idecabtagene vicleucel), the First CA..
PU
01/19Ceptur Therapeutics Inc announced that it has received $75 million in funding from a gr..
CI
01/11Evotec, Bristol Myers Expand Neurogenerative Partnership to Include New Targeted Protei..
MT
01/11Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination ..
AQ
01/11Evogene's Biomica Gets Israeli Nod To Move Ahead With Cancer Trial
MT
01/10BioAlta, Bristol Myers Squibb Partnering on Potential Cancer Treatments
MT
01/10BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab ..
PR
01/10Bioatla, Inc. Enters into a Clinical Collaboration with Bristol Myers Squibb to Investi..
CI
01/10Century Therapeutics, Bristol Myers Squibb Sign Cancer Research Collaboration Agreement
MT
01/10Century Therapeutics Shares Rise 12% Premarket After Bristol Myers Deal
DJ
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Financials (USD)
Sales 2021 46 399 M - -
Net income 2021 6 258 M - -
Net Debt 2021 28 505 M - -
P/E ratio 2021 21,8x
Yield 2021 3,10%
Capitalization 141 B 141 B -
EV / Sales 2021 3,65x
EV / Sales 2022 3,35x
Nbr of Employees 30 250
Free-Float -
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 63,54 $
Average target price 71,88 $
Spread / Average Target 13,1%
EPS Revisions
Managers and Directors
Giovanni Caforio Senior Vice President-US Oncology
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY3.58%141 036
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-11.98%220 356